|
|
|
|
|
|
|
|
|
|
|
|
|
27.01.26 - 22:09
|
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--#Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2025 financial results and provide a business update.
A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, C...
|
|
|
|
|
23.01.26 - 14:57
|
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025: Market to Reach $63 Billion by 2031 - ResearchAndMarkets.com (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--The "Strategic Intelligence: Cell and Gene Therapy Investment Trends" report has been added to ResearchAndMarkets.com's offering.
The market size of CGT products is expected to continue to rise by 2031 and reach $63 billion.
CGTs have yielded commercial gains for several pharma companies. For example, some of the top-selling CGT products include Gilead Sciences' Yescarta (axicabtagene ciloleucel) and Novartis's Zolgensma (onasemnogene abeparvovec) which reported sales of $1.5 billion and $1.2 billion in 2024, respectively. Additionally, Johnson and Johnson's Carvykti earned $963 million while Sarepta's Elevidys earned $820 million in 2024.
Innovative cell and gene therapies (CGTs) have significantly disrupted the treatment landscape for several genetic diseases.
CGT development is still focused on oncology, hematological/blood disorders (such as sickle cell disease, hemophilia, and beta-thalassemia), and neurology. The majority of pipeline cell therapies are autologous therap...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.01.26 - 10:45
|
GSK: Erfolg in Hepatitis B – wird Gilead nun abgehängt? (Sharedeals)
|
|
|
GlaxoSmithKline hat positive Ergebnisse aus den beiden entscheidenden Phase-3-Studien seines experimentellen Medikaments Bepirovirsen zur Behandlung von chronischer Hepatitis B vorgelegt. Noch im laufenden Quartal sollen global entsprechende Zulassungsanträge folgen. Das setzt Virologie-Riesen wie Gilead unter Druck. Die Zulassungsstudien in über 1.800 Patienten haben ihre wichtigsten Wirksamkeitsziele erreicht, was die Hoffnung auf eine funktionelle Heilung der […]
The post GSK: Erfolg in Hepatitis B – wird Gilead nun abgehängt? first appeared on sharedeals.de....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
